



Regulated Information

# Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC

**Leuven, BELGIUM – June 25, 2025 – 06:00 PM CET - Oxurion NV** (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation<sup>1</sup> it has received a transparency notification as follows:

Oxurion received a transparency notification on June 23, 2025, from Atlas Special Opportunities II, LLC indicating that as of June 19, 2025, it held 1,222,807 shares of the then outstanding 8,496,303 shares, and therefore crossed under the threshold (15%) by virtue of the selling of voting securities.

#### **About Oxurion**

Oxurion NV (Euronext Brussels: OXUR) is a biopharmaceutical group in transition, combining therapeutic innovation with technologies applied to clinical research. Through its rapidly expanding technology division, Oxurion is building integrated expertise around clinical data, with the ambition to accelerate, secure, and transform the processes involved in developing new treatments. The Group's headquarters are based in Leuven, Belgium. More information is available at <a href="https://www.oxurion.com">www.oxurion.com</a>.

### Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

#### For further information please contact:

Oxurion NV
Pascal Ghoson
Chief Executive Officer
Pascal.ghoson@oxurion.com

<sup>1.</sup> Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

## ANNEX 1

FSMA FINANCIALS MARKETS AI	SERVICES AND UTHORITY	Transparency notification Form TR-1 BE PART I	
1) Status of the notification			
Į.	Final	I	
2) Issuer			
Name Identification number	OXURION 0881-620-924	1	
3) Reason for the notification			
P	Acquisition or disposal of voting securities or voting rig	phts	+
4) Notification by			
<u> </u>	A person that notifies alone		+
5) Persons subject to the noti	ification requirement		
	Name	Address (for legal entities)	
	Atias Special Opportunities II LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577	+
6) Persons that dispose of vo	ting rights (only to be filled in if art. 7 of the La	w applies)	
	Name	Address (for legal entities)	_
			+
•	Please continue entering the information in part II ( persons referred to in Sections 5 and 6	concerning the Part II	
7) Date on which the threshol	ld is crossed		
Γ	19/06/2025	(DDMMYYY)	
8) Threshold that is crossed	(In %)		
		15	
•	If the holding has fallen below the lowest thre	shold, you have the option of not entering any numbers in Section 10	
9) Denominator			
	8,49	96,303	
0	Please enter the denominator before filling in	the data	
10) Notified details			
A) Voting rights	Previous notification	After the transaction	

A) Voting rights	Previous notification	After the transaction				
	# of voting rights	# of vot	ing rights	% of voting rights		
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities	
Atlas Special Opportunities II LLC	1,548,410	1,222,807				
TOTAL		1,222,807	0	14.39%	0.00%	

Start with "groupe" of holders. Add subtotals with  $\Sigma$ , and then finish with the persons who are "alone". For groupe, start with the utilimate controlling natural person or legal entity. The totals, subtotals and % will be updated once you have clicked on <a href="#">CALCULATE></a>.

+

B) Equivalent financial instruments	After the transaction								
Holders of equivalent financial instruments	Type of financial Instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement			
							+		
	TOTAL			0	0.00%		_		
17he totals will be updated once you have clicked on <calculate></calculate>									
	TOTAL (A & B)			# of voting rights	% of voting rights				
			CALCULATE	1,222,807	14.39%				
11) Full chain of controlled undertakings through which the holding is effectively held, if applicable									
	Attas Special Opporfunities II LLC is not a controlled el	ntity.							
12) In case of proxy voting for only one GM  Will cease to hold / county voting rights as of voting rights									
13) Additional information		will hold again		I	ı				
Sune 2025 (with settlement date on 10 June 2025), Atlas Special Opportunities II LLC sold 510,345 shares in Oxurton NV, as a result of which its shareholding decreased to 1,548,410 shares (= 18.23 or 1									
Done at Name & capacity F	ilew Yorls 20/06/20: Patrick Vance, Proxyholder	25 (DD/MMYYYY)	Sign	ature Patrick	e Varia				

For security reasons, the unsigned form in xisx format should be transmitted to trp\_fin@fcma.be. You can do this manually OR if you have MS Outlook at your disposal via the "Save & Send" button.

In addition, a signed copy in  $\underline{\textit{PDF}}$  format should also be transmitted.